Antifungal therapy during pregnancy

Coleman T. King, Phillip Rogers, John D. Cleary, Stanley W. Chapman

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Careful consideration of the benefit to the mother and the risk to the fetus is required when prescribing antifungal therapy in pregnancy. Imidazoles are considered safe as topical therapy for fungal skin infections during pregnancy. Nystatin is minimally absorbed and is effective for vaginal therapy. Although vaginal use of the imidazoles is probably safe during the later stages of pregnancy, their systemic absorption is higher than when applied to the skin. The systemic antifungal drug with which there has been the most experience in pregnancy is amphotericin B. There have been no reports of teratogenesis attributed to this agent. There is evidence to suggest that fluconazole exhibits dose-dependent teratogenic effects; however, it appears to be safe at lower doses (150 mg/day). Ketoconazole, flucytosine, and griseofulvin have been shown to be teratogenic and/or embryotoxic in animals. Iodides have been associated with congenital goiter and should not be used during pregnancy.

Original languageEnglish (US)
Pages (from-to)1151-1160
Number of pages10
JournalClinical Infectious Diseases
Volume27
Issue number5
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Pregnancy
Imidazoles
Teratogenesis
Griseofulvin
Therapeutics
Flucytosine
Nystatin
Skin
Ketoconazole
Mycoses
Fluconazole
Goiter
Iodides
Amphotericin B
Fetus
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

King, C. T., Rogers, P., Cleary, J. D., & Chapman, S. W. (1998). Antifungal therapy during pregnancy. Clinical Infectious Diseases, 27(5), 1151-1160. https://doi.org/10.1086/514977

Antifungal therapy during pregnancy. / King, Coleman T.; Rogers, Phillip; Cleary, John D.; Chapman, Stanley W.

In: Clinical Infectious Diseases, Vol. 27, No. 5, 01.01.1998, p. 1151-1160.

Research output: Contribution to journalArticle

King, CT, Rogers, P, Cleary, JD & Chapman, SW 1998, 'Antifungal therapy during pregnancy', Clinical Infectious Diseases, vol. 27, no. 5, pp. 1151-1160. https://doi.org/10.1086/514977
King, Coleman T. ; Rogers, Phillip ; Cleary, John D. ; Chapman, Stanley W. / Antifungal therapy during pregnancy. In: Clinical Infectious Diseases. 1998 ; Vol. 27, No. 5. pp. 1151-1160.
@article{46b548dc57b0474d90587fb7ac7a57dd,
title = "Antifungal therapy during pregnancy",
abstract = "Careful consideration of the benefit to the mother and the risk to the fetus is required when prescribing antifungal therapy in pregnancy. Imidazoles are considered safe as topical therapy for fungal skin infections during pregnancy. Nystatin is minimally absorbed and is effective for vaginal therapy. Although vaginal use of the imidazoles is probably safe during the later stages of pregnancy, their systemic absorption is higher than when applied to the skin. The systemic antifungal drug with which there has been the most experience in pregnancy is amphotericin B. There have been no reports of teratogenesis attributed to this agent. There is evidence to suggest that fluconazole exhibits dose-dependent teratogenic effects; however, it appears to be safe at lower doses (150 mg/day). Ketoconazole, flucytosine, and griseofulvin have been shown to be teratogenic and/or embryotoxic in animals. Iodides have been associated with congenital goiter and should not be used during pregnancy.",
author = "King, {Coleman T.} and Phillip Rogers and Cleary, {John D.} and Chapman, {Stanley W.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1086/514977",
language = "English (US)",
volume = "27",
pages = "1151--1160",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Antifungal therapy during pregnancy

AU - King, Coleman T.

AU - Rogers, Phillip

AU - Cleary, John D.

AU - Chapman, Stanley W.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Careful consideration of the benefit to the mother and the risk to the fetus is required when prescribing antifungal therapy in pregnancy. Imidazoles are considered safe as topical therapy for fungal skin infections during pregnancy. Nystatin is minimally absorbed and is effective for vaginal therapy. Although vaginal use of the imidazoles is probably safe during the later stages of pregnancy, their systemic absorption is higher than when applied to the skin. The systemic antifungal drug with which there has been the most experience in pregnancy is amphotericin B. There have been no reports of teratogenesis attributed to this agent. There is evidence to suggest that fluconazole exhibits dose-dependent teratogenic effects; however, it appears to be safe at lower doses (150 mg/day). Ketoconazole, flucytosine, and griseofulvin have been shown to be teratogenic and/or embryotoxic in animals. Iodides have been associated with congenital goiter and should not be used during pregnancy.

AB - Careful consideration of the benefit to the mother and the risk to the fetus is required when prescribing antifungal therapy in pregnancy. Imidazoles are considered safe as topical therapy for fungal skin infections during pregnancy. Nystatin is minimally absorbed and is effective for vaginal therapy. Although vaginal use of the imidazoles is probably safe during the later stages of pregnancy, their systemic absorption is higher than when applied to the skin. The systemic antifungal drug with which there has been the most experience in pregnancy is amphotericin B. There have been no reports of teratogenesis attributed to this agent. There is evidence to suggest that fluconazole exhibits dose-dependent teratogenic effects; however, it appears to be safe at lower doses (150 mg/day). Ketoconazole, flucytosine, and griseofulvin have been shown to be teratogenic and/or embryotoxic in animals. Iodides have been associated with congenital goiter and should not be used during pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=0032458556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032458556&partnerID=8YFLogxK

U2 - 10.1086/514977

DO - 10.1086/514977

M3 - Article

VL - 27

SP - 1151

EP - 1160

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 5

ER -